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Abstract
Polygenic tests such as genome-wide small nucleotide polymorphism (SNP) risk testing,
exome or genome sequencing are currently on the horizon for genetic testing for inherited
cancer risk. We are unsure of how patients would accept this future genetic testing and
the best way to fully understand the experience of undergoing a polygenic test for breast
cancer risk is to explore the experience of women who have already undergone the
process. In Ontario, these individuals are those who have already had gene panel testing
(GPT). This group’s opinions and experiences will be directly related to the refinement
and modification of the existing GPT process and will provide guidance for polygenic
testing offered in the future. Methods: Fourteen women who have undergone GPT in the
past year were interviewed in a semi-structured manner regarding their GPT experience.
Interviews were recorded and transcribed, then qualitatively coded to identify key words,
phrases, and expressed concepts surrounding GPT. Results: Participants had an overall
favourable opinion regarding their GPT experience, with minor changes to be considered
in future provision of GPT. In general, GPT appears to be well-tolerated within the
context of a traditional genetics assessment and participants that did not receive a
clinically significant result through GPT felt that they would be open to pursuing other
forms of genetic testing in the future such as polygenic testing, despite the possibility of
receiving an uncertain result.
Key Words: Genetic counselling, inherited breast cancer risk, gene panel testing, future
genetic testing
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Introduction
Gene panel testing refers to the concurrent sequencing of a predetermined set of
genes via a next-generation sequencing technology. In recent years, several commercial
genetic testing labs and academic institutions have introduced gene panel tests. Cancer
risk panels usually include cancer-predisposition genes that have a high and/or moderate
penetrance. High penetrance genes confer a lifetime cancer risk of anywhere from
seventy to one hundred percent (i.e. BRCA1, BRCA2, TP53, etc.), while moderate
penetrance genes confer a lifetime cancer risk of anywhere from thirty to sixty percent
(i.e. CHEK2, ATM, PALB2, etc.).
There are many advantages to gene panel testing when compared to sequential
single-gene testing, a practice which was only recently made obsolete by the introduction
of gene panel testing. Firstly, panel tests are typically found to lower the cost of
sequencing per gene. In other words, customers are receiving more for their money. With
panel testing, there is also the potential to identify patients who have mutations cooccurring in different genes, potentially impacting their healthcare management. In
regards to clinical efficiency, there is a quicker turnaround time for panel testing versus
sequential genetic testing, which may also impact the patient’s healthcare management or
decision-making process. There is also less hassle for the patient and provider since
informed consent can be performed all at once instead of each consecutive time a new
test is ordered. With gene panel testing there may be improved detection of mutations in
patients with abnormal cancer phenotypes, absent family history data, a family history
that does not meet testing criteria, or when the family history meets criteria for several
inherited cancer predisposition syndromes. Lastly, many genetic testing companies have
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flexibility in what they offer on their panels, such that clinicians may add or subtract
certain genes from the panel according to their preferences and the patient’s needs (Hall
et al., 2014).
Conversely, there are some drawbacks to panel testing. First, incidental findings
may often arise when administering a panel test, either in addition to or instead of a
mutation that explains the patient’s phenotype. Particularly in the field of cancer genetics,
incidental findings can cause challenges when mutations are found in genes where there
is limited or no data regarding medical management. This is specifically relevant for
moderate penetrance genes in which expression may be also be influenced by external
factors such as the environment (Hall et. al., 2014). Patients receiving uncertain
information regarding genetic risk information and clinical management may find this
information difficult to accept (Hiraki et al., 2014). Additionally, with the increased
number of genes now available on panel tests comes an increased prevalence of variants
of unknown significance (VUSes). These VUSes can often be misinterpreted by the
provider and/or patient as a true pathogenic mutation that is causing the patient’s or their
family’s phenotype. This can lead to erroneous risk management recommendations by the
provider. This is particularly troubling when we acknowledge that over time, the majority
of VUSes are classified as a benign variation in the patient’s genetic code (Hall et al.,
2010). A small fraction of VUSes will be reclassified to pathogenic, and relaying this
data to the patients often requires time and manpower.
Equivalent rates of BRCA1/2 mutations and BRCA1/2 VUSes are found in
patients that have solely BRCA1/2 testing versus those that have gene panel testing. Gene
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panel testing increases diagnostic yield and increases the rate of VUS findings (Kapoor et
al., 2015; Buys et al., 2017). Approximately half of individuals who test positive for a
non-BRCA mutation receive cancer screening and prevention recommendations that are
altered from management that was previously determine solely from their family history
(Desmond et al., 2015).
Collectively, these findings highlight not only the efficacy of gene panels at
identifying BRCA mutations, but also the impact that identification of non-BRCA
mutations has on diagnostic yield and patient care.
Breast Cancer Genetic Testing: The Decision to Test
One of the biggest initial questions after the introduction of BRCA1/2 genetic
testing was regarding patients’ motivations for testing. Women who undergo BRCA1/2
testing are at a higher risk of being carriers for a BRCA1 mutation, are more likely to be
Ashkenazi Jewish, are more likely to have a known family mutation, are more likely to
want ovarian cancer risk information for themselves, and are more likely to want breast
and ovarian cancer risk information for family members. They are also less likely to be
worried about insurance or job discrimination (Armstrong et al., 2000).
Research by Augestad et al. (2016) on women who were newly diagnosed with
breast or ovarian cancer and who had been offered and accepted genetic testing found
that patients are overwhelmed with the amount of information regarding all things breast
cancer-related. Patients indicated that they need support and counselling from a
healthcare professional in order to assist their decision-making process. Researchers
believe that the ability to obtain such services might enable women to improve their
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ability to sort through emotions and comprehend the overwhelming details of their breast
cancer and genetic testing experience.
Psychosocial Implications of Cancer Panel Gene Testing
Unaffected individuals with a family history of hereditary breast and ovarian
cancer who receive positive genetic testing results are most considerably affected by
intrusive thoughts and feelings of avoidance and distress. Additionally, genetic testingspecific stress is generally increased in patients that are of a lower age, of AfricanAmerican race, of lower education level, of lower genetic knowledge, or of Hispanic
origin (Lumish et al., 2017).
Cancer Genetic Testing in Ontario
In Canada, women who have personal or family histories consistent with a
hereditary breast or ovarian cancer syndrome may be referred for genetic counselling and
genetic testing, which are available through the socialized health care system. The
Ministry of Health and Long Term Care has published a set of guidelines for individuals
in the province of Ontario who should be offered genetic counseling and who are eligible
for genetic testing. These guidelines base recommendations on the individual’s personal
and/or familial cancer history (Genetic counseling eligibility, UHN). Genetic testing for
BRCA1/2 was introduced to Ontarians in 2001 and since then over 30,000 individuals
have been tested (Finch et al., 2015). However, only in the past two to three years have
Ontario genetics clinics begun utilizing gene panel testing (GPT).
Understanding GPT and Possible Future Testing Options
Currently, additional testing methods are being developed to provide a more
thorough look at inherited cancer risk by using polygenic tests such as genome-wide
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small nucleotide polymorphism (SNP) risk testing, or exome and genome sequencing.
The best way to fully understand the process and experience of undergoing a polygenic
test for breast cancer risk is to explore the experience of women who have already
undergone the process. In Ontario, these individuals are those who have already had
GPT. This group’s knowledge, opinions and experiences will be directly related to the
refinement and modification of the existing GPT process. Additionally, it will provide
guidance for future polygenic testing that may be offered in the future.
As previously mentioned, GPT has been introduced to many high risk cancer
genetics clinics in Ontario within the past couple of years. As we know, many of the
genes included on GPT panels can lead to results of uncertain significance or positive
results in moderate-risk genes and thus may have uncertain clinical management
implications. We are unsure of how patients would accept future genetic testing or how
they would utilize the information resulting from it. Given the complexity of themes
surrounding the GPT process, qualitative analysis would be ideal for exploring patient’s
opinions and preferences surrounding the introduction of this future genetic testing
method in Ontario. In addition, these explorations will also inform the provision of
possible future polygenic tests for breast cancer susceptibility. Furthermore, concepts and
themes discovered during this process could guide future quantitative research on the
topic.
Methods
This study aims to explore the opinions, preferences, understanding, and
psychological/health behavior impacts of gene panel testing for individuals that received
genetic counseling and genetic testing for breast cancer risk. Additionally, this study aims
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to explore opinions regarding the provision of a future hypothetical polygenic breast
cancer risk test. The protocol for this study was developed by Gord Glendon, MSc of the
Lunenfeld-Tanenbaum Research Institute and Mount Sinai Hospital, Mount Sinai Health
System (MSH).
Participants
A chart review of all female patients who had undergone breast cancer gene panel
testing (GPT) at the Marvelle Koffler Breast Center at MSH was performed to identify
eligible participants. Eligible participants were considered to be those who had their
results session within a year of the study invitation date and who were fluent in the
English language. Ineligible participants included women who were actively undergoing
cancer treatment or who were not fluent in the English language. Eligible participants
were mailed an invitation letter, a study consent form, and a stamped return envelope.
Individuals who returned completed consent forms were contacted via phone to set up a
time for a taped qualitative telephone interview. Individuals who did not return a consent
form were re-contacted by telephone within an approximate three-week period to
determine if the invitation arrived and to address any questions the invitee might have.
Purposive sampling was attempted to ensure that the study included participants that were
both affected and unaffected by breast cancer and had received both clinically
informative and uninformative results. There was a total of fourteen participants. The
demographics of the study participants are shown in Appendix 1.
Interview
The study team previously created a list of pertinent issues to be discussed in a
semi-structured interview. These issues were developed and refined into interview
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questions. The interview guide comprised of questions that aimed to understand the
participants’ GPT experience, impacts of GPT, opinions and preferences regarding the
provision of GPT, as well as participants’ opinion regarding the provision of a future
polygenic test. The following is an example of an interview question and related prompts:
‘Do you feel that the GPT helped to explain your personal or family history of breast
cancer? Do you feel the GPT added any information beyond what you may have learned
from your BRCA1/2 test? Do you feel that this test added anything to your understanding
of your cancer / your family’s cancer / your breast cancer risk?’ Participants were
encouraged to bring up additional topics related to GPT that they wanted to discuss. No
additional topics came up during the course of the interviews that would have
considerably altered the interview guides. Each interview was conducted by Gord
Glendon, Angelina Tryon, or both. Interview questions may be found in the Appendix.
Data Analysis
The interviews were transcribed verbatim and the transcripts were read closely by
the interviewing team to facilitate the coding process. Transcription quality was ensured
by comparing the interview audio with the transcribed text for 4 randomly selected
interviews. The development of codes took place in joint reviews after each interview by
the interviewing team, which facilitated the complete set of themes and sub-themes that
made up the majority of the study findings. The codes and themes were elucidated in this
fashion. Coding was able to identify key words, phrases, and expressed concepts
surrounding GPT. Interviews continued until thematic saturation was complete.
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Genetic Testing
All genetic testing was performed at MSH. All participants received the same
gene panel test, comprised of the following genes which confer for increased lifetime
risks of breast and/or ovarian cancer: BRCA1, BRCA2, CDH1, EPCAM, MLH1, MSH2,
MSH6, PALB2, PMS2, PTEN, STK11, TP53, ATM, BRIP1, CHEK2, RAD51C, RAD51D,
BARD1, FANCC, NBN. Each panel included both Next-Generation Sequencing and
deletion/duplication analysis.
IRB Approval
This study was approved by the Mount Sinai Hospital Research Ethics Board on
June 14, 2017 and was approved for expedited review by the Sarah Lawrence College
Institutional Review Board.

Results
Understanding the Participants’ GPT Experience: Timeline and Testing
When asked about motivations behind pursuing GPT, participants indicated a
variety of reasons. The majority of participants indicated that they wished to pursue GPT
because it had been recommended by their physician and because pursuing GPT would
satisfy their information-seeking behaviours. One participant noted, ‘Dr X was in the
Mount Sinai clinic the day I had the appointment. And he went over things with me,
recommended that under the circumstances genetic screening would be useful and
brought in [GC X] while I was still there…Now I'm single and adopted, I have no genetic
information. So this was extra useful. Not that I have any kids to warn but just for my
own peace of mind’. Other participants indicated that the reason for pursuing testing was
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for the sake of their children or other family members. One participant stated, ‘And I
know that was one of the decisions – or one of the factors that impacted on my decision
to do the gene testing, was whether it could have any relevance for other family members
who might, depending on my results, then need to go through gene testing themselves, if
they so wished’. Additional reasons for pursuing GPT included that it would allow the
participants to make decisions regarding treatment of their breast cancer or decisions
regarding cancer screening.
Participants displayed an overall good understanding of the GPT test. The
majority of participants explicitly acknowledged that they knew GPT was different than a
BRCA1/2 genetic test in that it looked at more than two genes. Some participants even
correctly recalled that the GPT looked at 20 genes specifically. One participant stated,
‘… it's a screening for 20 particular genes that they know cause -where they know
mutations can cause an increased risk of cancer. And from what I know it can tell you
you have an increased risk of cancer, it doesn’t tell you you'll definitely get it or if you
don’t test positively for the genes that you won't get it. It's just people who do test
positive for genes like BRCA 1 or 2 tend to have a much, much higher incident of breast
cancer and therefore there's also special preventative measure that they can take if they
find that they have the gene, so, yeah and so it's just, as far as I understand, just looking
whether you fit into your particularly high risk group or not’. At least half of participants
expressed that they knew that GPT results can have impacts on cancer recurrence risk and
risk of future cancers. More than half of participants also explicitly understood that
different genes on the panel can have different impacts in regards to types of cancers that
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a person may be at risk for. Two participants even acknowledged that this test may have
implications for obtaining insurance in the future.
All participants had their GPT results delivered over the phone, by a genetic
counsellor. Most participants who tested negative did not come for an in-person followup appointment in additional to the initial results phone call. Some participants indicated
that they preferred phone results, given that the process is quicker than coming for a
results appointment. One participant was glad that her results were delivered over the
phone, but did emphasize that results might be best delivered based on patient preference.
She noted, ‘…it was quicker, it was, you know, done quickly, you had an opportunity to
process it in your own way …What I might suggest and I don’t know, but I might suggest
giving the person an option, you know, "Would you prefer that we - that the result is
shared with you over the phone or would you prefer to come down and have an
appointment?" [Interviewer: Mm-hmm, yeah it might help accommodate those people
who-] Yes, who need a face-to-face, they need more explanation, they - you know that
kind of thing. Now obviously if that had come back positive, you know she had indicated
to me she would like to have a follow-up appointment’.
Some participants recalled the entire process from genetics consultation up until
results disclosure to be around two months, while other participants recalled this process
taking as long as five months. Several participants indicated that they wished the process
had taken less time, with a minority even specifying that they had some anxiety during
the waiting period for results. One woman stated, ‘You know, I was a bit anxious during
that time period. I wouldn't say it super negatively affected my quality of life particularly
because I'm just anxious in general. And so it's not that much of a difference. But yeah,
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the long waiting period was a bit nerve wracking in some ways. In other ways though it
was, like okay really I have to wait to make this decision and I'd rather have the
information sooner rather than later when it comes down to that’. On the other hand, a
couple of participants did not think much about the test or possible results during the
waiting period. One woman noted, ‘Yeah, whatever it was I had no investment, I
obviously wanted it to be a negative but, I mean, I…forgot about it and… then I got the
results’.
Impacts of GPT for Participants
Overall, participants affected by breast cancer displayed an accurate
understanding of what their GPT results meant in regards to their personal history of
breast cancer. One participant who tested negative and when speaking about her previous
cancer diagnosis stated, ‘So, it's not genetic it looks like. So, it's just the luck of the draw
and I will just keep an eye on things because there is the possibility that as genetic testing
improves and they find more related genes, there will be more information forthcoming’.
However, one participant affected by breast cancer and who tested positive for a CHEK2
gene mutation displayed incorrect understanding regarding her test results and what that
meant in regards to her breast cancer diagnosis. She stated, ‘…the cancer I've got isn't
genetic…Breast cancer is not, you know, a genetic … disorder or I don't have a genetic
predisposition for it or anything like that. It's just one of those things’. Generally,
participants affected and unaffected by breast cancer understood the meaning of their
GPT results in relation to their family history and their future risk of breast cancer. One
unaffected participant who tested negative noted, ‘I didn’t have any of the mutations and
so now it's just I'm part of the high risk screening program because of my family history’.

13

A minority (2) of participants displayed uncertainty or incorrect knowledge in regards to
the meaning of negative test results. One participant, when asked what the results mean in
regards to her risk for breast cancer stated, ‘I don’t have a risk, or my genes say I don’t
have a risk at all actually’, and when asked about whether she thought her risk for cancer
was either at or above population risk, she stated, ‘I don’t know maybe population risk, I
don’t know’. Furthermore, several participants had a general understanding as to whether
their results would or would not have implications for family members. One participant
affected with breast cancer, who tested negative with one VUS in ATM stated, ‘…the
results are relevant to, like I said before, family members who now, you know, don’t
necessarily need to undergo genetic testing, because it doesn’t look like I can carry a
family-based gene. So that suggested others don’t necessarily need to undergo testing
immediately, or at any point necessarily, although they will be eligible for advanced
screening methods as in my own diagnosis’.
A majority of participants who tested negative or received a VUS result did not
feel as though the GPT explained their personal or family history of breast cancer. One
affected participant noted, ‘So for me, it did not, because I don’t have a family history of
breast cancer. I am very young. You know, statistically speaking, I should not have breast
cancer. And so this couldn’t clear things up for us, it just made it more of a mystery’.
Another affected participant explained, ‘…it still leaves the unanswered question right
because I mean I'm a very fit person, I breastfed each of my kids for two years, I never
took the pill, all of those things that medically are supposed to put a woman at higher risk
were not the case for me, so that kind of leaves the big question mark 'well why'…’. A
third affected participant, though her results were negative, indicated that these results
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may have inspired her to pursue reconnecting with her biological family since she was
adopted at birth, ‘…it eliminated some possibilities, the hereditary possibilities. I always
wondered but I've never followed up on looking for my biological family…And this
might have triggered that search’. A majority of participants who tested negative felt that
their GPT results gave the peace of mind. One woman stated, ‘…certain genes, if they
come back positive, it also increases your breast – or suggests that you're at higher risk
for getting ovarian cancer. You know, I certainly don’t want any other kinds of cancer.
So in that sense, knowing that I don’t have any genes, means that I'm not, as far as we
know, predisposed to getting ovarian cancer, so that was a huge relief for me’. Another
woman noted, ‘Well - no I feel much, much better and I feel that, you know, it's an
answer to a fear that I had and the thing is that I did decide to have a child even though
with this big thing weighing on my mind that this child - that I may pass on this illness or
disease to him and his future family, and so knowing that he's not a carrier has just - it
has lifted a huge worry off my shoulder…’ Additionally, participants that tested positive
for a gene mutation as a result worried more about their breast cancer risk or risk for
other cancers. One participant affected by breast cancer who tested positive for an ATM
mutation stated, ‘I'm just a little worried about a couple of the other cancers I can get
because there's nothing they can do about them. You can't test for them’.
Participants with VUS results were asked whether they felt any feelings of
uncertainty in regards to these types of ambiguous results. One individual stated that she
felt her VUS results gave her some anxiety. She stated, ‘It gives me a little bit of anxiety
and for sure, I have it in mind, what does that mean. I know I cannot do anything, and
this might take years before we understand what exactly that is. And maybe in the future

15

you'll find something that might help us understand that’. On the other hand, another
participant stated that the VUS result didn’t make her feel anxious. She noted, ‘How do I
feel, not too...not too badly. I mean I'm not really that concerned about this. I mean I said
… I wanted to have the genetic testing and I said, "As far I'm concerned the more
information the better", and so yeah I don't - it doesn't make me anxious or anything …
I'm not ignoring it … you know it’s unclear whether this possible variant changes
anything, I don't think so as far as I'm concerned moving forward’. A third participant
related the uncertainty of GPT results to inherent uncertainty in life. She said, ‘I have
discovered that life is uncertain, really. Yeah at this point in my life I'm much better at
taking it as it comes. [Interviewer: Right. So you were willing to undertake a little bit of
uncertainty in your sort of quest to understand better what was going on. Is that kind of a
good summary?] Yes. That pretty well sums it up, yes’. One woman also made a point to
say that she thought clinics should take responsibility for recontacting patients regarding
VUSes. She stated, ‘Yeah it’s probably not the greatest system just to sort of leave it up
to me to contact her but, you know, it is what it is.
…I think it might be better system to have the clinic contact the person but I'm prepared
to diarize it’.
All participants who were asked about whether they shared their test results with
family and friends admitted that they were open about their testing process and results
with either select friends and family or all friends and family. One participant was
particularly open about her testing process and results, ‘Oh yeah, yes I - my whole family
knows about it and...yes and I have a sister too so she's well aware of what's happened
and the results of it and everything. Yeah and I've told my friends as well, you know,
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because it’s good news right [laughs] that I don't have any of the genes, so yes I shared it
with everyone in my life actually’. Another participant who tested positive for a BRCA2
mutation was a bit more reserved with telling anyone outside of her aunts and husband.
She noted, ‘Yeah, I don't know. I just wasn't comfortable telling them yet. I don't know
why. It's one of those weird things I'm not quite sure. I think because I want to figure out
what I'm going to do about it first before people ask me what my plan is’.
The majority of participants explicitly expressed their knowledge of what actions
and/or medical screening were recommended by their medical team based on their GPT
results. One affected participant who received a VUS result stated, ‘… if it had come
back positive…I would probably have said, okay, I’m going to --- double mastectomy,
and I’m certain that would have been the recommendation of my doctors as well… So
that certainly has impacted on that decision, and again, my doctors as well, because now
their recommendation is only to do a single, whereas if the results had been different,
they would have said do a double. So it certainly impacted on me in that sense’. An
unaffected participant who tested negative also stated, ‘… I got a phone call from my
genetic counsellor and … she was going to refer me because of my family history to the
high risk screening program but that there wouldn’t be any other steps that we needed to
take’. On the other hand, an affected participant who tested positive for a CHEK2
mutation recalled being told that she would need to make an appointment for a
colonoscopy, but when asked whether she would need more frequent colonoscopies than
other people her age, she stated, ‘I have no idea’.
Participants were also asked about health behaviour changes post-GPT return of
results. Two participants expressed that they would change their health behaviour such as
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diet and/or exercise based on their GPT results. A participant affected by breast cancer
who tested negative stated, ‘Well the thing is that the test results I feel like they are
backing-up, you know, my diagnosis of breast cancer, so once I was diagnosed with
breast cancer it's like I'm forced to change everything about my diet, you know my
activity level, everything, even my mental wellbeing right, emotional and everything…I
think that the genetic test results are like complimentary to it where it says to you, "You
know what, you don't have this gene, you don’t have any of these genes", so look at the
environment factors, look at your diet, look at all these other things’. One participant was
unsure about whether the results would change her health behaviours, while several
participants indicated that they would not change health behaviours based on their results.
One unaffected participant, when asked whether the result would change her health
behaviour replied, ‘No, no. I mean it's always good to stay positive and proactive about
your health regardless’. Another participant, affected with breast cancer who tested
positive for a CHEK2 mutation stated that ‘…Most of the changes have been made
simply because of the triple negative [breast cancer]’. Some participants indicated that
they would change their cancer screening based on GPT results, with one participant who
tested positive for a CHEK2 mutation indicating, ‘… in terms of impact that's about the
only thing - for me it was to say, okay, we'll make an appointment to have a
colonoscopy’. A participant who tested positive for a BRCA2 mutation also indicated, ‘…
in a week I had MRI and a mammogram booked. Already. Like done. She had those
booked for me within a week for my breasts. And so I went down there. So that whole
week was very - like stressful because all of a sudden I'm going for these test, one right
after the other. And then I have two appointments coming up in February’. Other
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participants indicated they would not be changing their cancer screening habits either due
to personal preference or due to doctor’s recommendation. One unaffected participant
who tested negative stated, ‘No, I'll just have my routine screenings like I usually do and
that's it. It'll stay the same just to be on the safe side even though it says no but it's always
good to keep checking’.
Opinions and Preferences on the Provision of GPT
Participants were retrospectively asked about their understanding of what their
possible GPT results could have been (ie. positive, negative, and/or VUS). Several
participants felt they understood what the possible test results could be, with some
participants even identifying possible results as being either positive, negative, or VUS.
One woman explained, ‘… there’s the positive and there’s the negative, and then there’s
the ones where they’re unsure, or something like that. Yeah, that was a little like “Okay,
well what do you do with that information” that I guess sounded like . . . I don’t know. I
think the way it sounded was that they would continue to have developments in research
and somehow – I don’t know, someday that would make sense. I don’t know, I can’t
recall, I just know that there was one that was like the one answer to the testing that was
like inconclusive kind of’. Conversely, one participant did not feel as though she
understood much about possible test results, She stated, ‘…at the time I thought I told her
[the genetic counsellor] that I had a science background so I kind of understood a little bit
but… I realize that I don't really understand very much about this’. Most participants
recalled that at the time of the genetics appointment, they felt they had a good
understanding of what kind of clinical recommendation could be gleaned from test
results, with one woman affected with breast cancer stating, ‘Yes she was very clear
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about that, she talked about if the test negative, you know, obviously I didn't - wouldn't
have had the X gene, if the test was positive she said she'd like me to come back and talk
about the possibility of a hysterectomy and I said well that's kind of down the road, I
have not made that decision yet but I really appreciated her kind of saying that, you
know, rather than just, "Here's your result, see you later, good luck", you know, that she
said she would like to see me again for a follow-up appointment for sure and, you know;
so that was - she kind of gave the scenario for one and two, option one and two’. On the
other hand, one unaffected woman who tested positive for a BRCA2 mutation noted, ‘…I
knew that if it comes back positive that they're going to tell me you have a risk for this or
a risk for that… what I didn't expect was, like, the discussion of, like, so fast that you
have to - you should do this now and you should do this, and be thinking about this, this,
and this type of thing. About different surgeries. Like I just felt like wow, that was - just a
lot to think about. I knew - I expected different - like I expected if she said you're positive
with this gene that you're going to get this - this is what you're at risk for. Yes. I
did. [Interviewer: Do you feel like you had a good understanding of what possible
clinical recommendations could be made based on the results] No, that's what I would say
no’.
Most participants indicated they would not change anything in regards to their
preparation or pre-test counselling for the GPT. One participant stated, ‘Yeah, so I mean,
for the most part the experience, you know, was really well-managed and, almost – to use
your previous word – positive. You know, it’s a very complicated thing to explain to
people who have no knowledge whatsoever of genetics, and so we were given some
really useful resources and things that were pretty – you know, some very informative
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information that was pretty clearly spelled-out’. Another participant wished she had been
given information in advance of what a genetic test was, ‘The information of what is a
genetic test, maybe to give you some information before you go to the test itself, and
what are they. Maybe provide some more information. …It could be printed, it could be
online, some additional information or reference to some websites that you link to,
maybe. Or just a quick handout, you know, a handout with simple information, but put
everything plain and simple…’ Alternatively, another participant wished she had been
given a handout after the appointment, ‘I think I would have liked to have gotten a little
bit more information on paper about the tests themselves just because it would have
saved me some excessive Googling after the appointment’. One woman indicated that the
information went over her head, ‘So yeah, so she had explained about, you know, how
the genes fit into the DNA sequence, but I didn’t really understand that….And it wasn’t
really practical in terms of assisting me in my decision-making process, but she did
explain how things kind of all fit in, etcetera’.
Several participants indicated that they would not change how results were
returned or anything about the patient letter. However, some participants took issue with
the complexity of information presented in the patient letter. One woman noted, ‘… I
received the results, and I received the papers and there’s so much information that it’s …
I cannot understand it. It’s just the experts will decipher that thing, because it’s like a
code, you know what I mean? It doesn’t make any difference to me to have all these
pages printed with its code and information I cannot understand. So just put it plain and
simple, and keep the rest for yourself. I mean, the technicians need that information,
that’s fine for them, I don’t need it’. Another participant agreed and would have preferred
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a patient letter in layman’s terms, ‘The only thing I would say is that the results were not
as clearly spelled-out as the initial information. So you know, they have, like, really –
you know, some good diagrams and explanations and stuff done to explain why would
you undergo genetic testing. And then we did get full results after the fact, which was
great – I'm really happy to have them, because those full results are definitely more
technical in their write-up, there’s not really the layman’s version of them’. A couple of
participants also had thoughts on receiving results that have no clear implications for risk
or management. One woman explained, ‘…if it's not clear it just freaks people out’, while
another stated, ‘… I don't know if that would just make you more crazy. I don't know, I
can't answer that because I think that depends on the person’.
Participants had an overall favourable opinion regarding their GPT experience,
with many going as far as to recommend this test to others in a similar situation. One
participant noted, ‘You know overall I was impressed by the process. I hadn’t had too
much experience with this kind of program in the health system in Ontario particularly.
I'm a relatively young, healthy woman so I didn’t have too much reason to. And overall it
was a positive experience. I think it was helpful. And certainly all the staff I worked with
and everyone I talked to has been really professional and explaining things at a level
that's not, you know requiring an MD which I always appreciate. So it's been a good
experience’. One participant affected with breast cancer stated, ‘…it was a good
experience, it wasn’t a traumatising experience or anything like that, it was really a very
simple process. And when you have cancer, you're already going through so … it’s like
the easiest part of it. So why not, really?’ Another participant noted, ‘…I'm from Mexico.
So this is something that in, in Mexico, the women that have had breast cancer in my
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family, and I had a choice to receive this type of genetic test. I mean, I believe that we
have a privilege here in Canada to have this option, and for sure, I would recommend it to
my friends’. However, many participants indicated that the decision to pursue GPT may
depend on the individual and their particular situation. A participant commented, ‘… I
love the idea that knowledge is power but I also understand that if you’re not in the right
state of mind to deal with this it could actually force you to put your head in the sand and
not want to deal with it…if you’re in a negative state of mind, if you’re depressed or
whatever, this is not the right time for you to get the results right; but if you’re in a
position where you're like fight or flight type of mode where you're like, "My health is in
jeopardy I need to do something about it"; so I think that that will empower you to move
forward in the steps of deciding, you know, what's best for you…’
Future Polygenic Testing
Participants who tested negative or received VUS results via GPT were asked
their opinion on whether they would be interested in pursing future polygenic testing that
would look at SNPs or thousands of genes across the genome. This testing would help
participants try and understand how cancer runs in families. Participants indicated that
they would be motivated to pursue this future polygenic testing. Several of these
participants indicated that they would be motivated to pursue this testing in order to find
answers that GPT did not give them. When asked why she would be motivated to pursue
future testing, one unaffected participant who had negative GPT results noted, ‘I would
say just because for me I - and particularly going through this process I just realized it
was much more comforting to me to think about having the information even if it wasn’t
the results I wanted or it wasn’t - or if it was something that was serious about my health.
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To me that's better than finding out five years after I could have been diagnosed that I
suddenly have cancer, you know. And I've seen that happen to a lot of women over my
life and that's not - you know, as much as I can avoid that kind of medical surprise I
would prefer to’.
Participants were also asked about their willingness to pursue this future testing,
given the possibility of receiving uncertain results as with GPT. Participants seemed
fairly alright with this possibility, with some willing to risk the possibility of receiving
uncertain results if it meant there was a chance they could get an answer. One affected
participant who tested negative stated, ‘I mean, really, like, you already have uncertainty,
right. From my perspective, you don’t know what’s in your genes, but whatever is there,
is already there, there’s nothing you can do about it. So getting any more uncertainty,
like, doesn’t change anything, right, you're already in that position where you don’t
know, so … And if you get results that are meaningful, then it gives you something that
you can take action on’. Again, another participant commented that this uncertainty may
not be for everyone, ‘I will tell you, I think it will cause more anxiety and not everybody
might handle that type of information very well, but in my case, I would like to know it
and start preparing’.
Participants were asked whether they would pursue this future testing if it could
also provide information regarding risks for other diseases aside from cancer, even
diseases that do not have treatment or medical screening available. Many individuals
were also interested in pursuing this testing, however many acknowledged the
psychological difficulties that may come with learning this information. One participant
noted, ‘No, no, I would like to know about any other disease that I could have in the
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future. Whereas I know it’s important, what are the worst things that I could deal in the
future…but just the fact that you know it, might change some decisions that I take now or
in the future. It’s something that will probably cause me anxiety, yes, but I still want to
know’. Another participant said, ‘Yeah, you know, I think I would probably ultimately
decide that I wanted to know. But I think finding out something about a disease that has
not really been in my consciousness or in my family history would really, would be a bit
more of a psychological difficulty to take I guess. Like I would find that bit more of like
oh, I'm worried about breast cancer but actually I'm going to get Alzheimer's…’ One
participant also highlighted that medical screening may not be the only way to ‘prevent’
disease. She said, ‘…it depends on how you define what you can do about it. There's
spiritual ways and… there are physical and medical ways and social ways…I think that
there are all these things that can be done, depends on how you define that’. One
participant was not interested in learning about risks for other diseases at this point in
time, ‘When it comes to testing, you know, my probabilities for every disease under the
sun, I think, you know, there’s certainly an aspect that appeals to me. Like I said, having
that information you can ---, you can take action. But I mean, at the moment I'm certainly
not in a position where I would want to do that, because I have enough to deal with, right.
Like, I don’t need to know that I'm also at risk of getting Alzheimer’s and whatever else
they would test…’.
In regards to the provision of this future polygenic test, participants had varied
opinions. A few participants brought up the point of having this test provided with the
context of a hospital system or specialty breast clinic. One participant admitted, ‘I also
feel strongly that you deal with one hospital system and stick with it and everything you
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do – as I joke I say I go to X for all my cancers. But, you know, it's not such a joke, I
think that it really is, I like to go to the hospital, I like to go to the same hospital each
time so they have everything from whatever I'm dealing with…They're able to coordinate
everything all in one…’. Another participant stated, ‘… I think the best one ideally would
be to a breast, like clinic, because they have people who are experienced working in it
versus – like I like my GP but I mean some people don’t have a GP so they’d go through
like a walk-in clinic. I don’t know. So, ideally it would be better to be in an environment
where they work with breast cancer on a regular basis’. A third participant emphasized
the necessity of a genetic counsellor or trained genetics expert to be involved in this
testing process, ‘I think a genetic counsellor is somebody who really does know genetics.
I think more specific knowledge, I think, is very important. Because genetics is very
confusing…’. Conversely, many individuals thought that this test could potentially be
provided by their family doctor. One participant stated, ‘So I think the obvious place
would be the family physician right, like I mentioned …a person has that trust factor
hopefully with their doctor and, you know, in terms of around getting that test out to
people….’ Another participant noted, ‘….should be a discussion that you should have
with your family doctor, and all family doctors should be prepared on how to deal with
this type of testing, with the questions from the patients, with the results’. Many
participants thought that this future polygenic might be beneficial if publicly available,
however certain concerns such as public education, cultural concerns, personalized
service, and possible online accessibility would need to be addressed. One participant
noted, ‘…public education a no-brainer, like I - you know if you'd have forums in
different parts of the province where people could come and just, you know, have a Q&A
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and a bit of a presentation or people could go online and log in. I think I might do a few
different venues, I think I might have like kind of a town hall thing where the
professionals come and they explain what would go on and that sort of thing. For those
people who couldn't get out to a town hall or something they could go online and maybe
participate in a webcast or something; God with technology now there's so many options
right’. Another participant emphasized education for family doctors, ‘…I do think the
education component would be important, you know, making sure the doctors, even if
they're not genetic counsellors have a sheet or some information or a website to refer
people to that explains in basic terms what the testing is’. One participant emphasized, ‘I
think a personal interaction is better because, you know, sometime we can read things on
the net that we shouldn’t interpret them differently. I think it's better to have one face to
face so that you can ask questions if you have them’. Lastly, one participant emphasized
cultural needs, ‘…Medical information is something that is personal but it's also a tool for
having a long and healthy life. I think some ethnic groups have more trouble with trusting
doctors …And how to get it across in multiple languages in Ontario…getting it across to
a language group as well to older women who have not worked outside the home and
never got comfortable with English’.
Miscellaneous Themes
One participant brought up the point of the utility of other parts of the genetics
assessment (ie. risk models) as having influenced her medical treatment for breast cancer.
She stated, ‘… the results also came back with a calculation of my risk of developing a
new primary breast cancer, so the breast that is currently not affected. So that is definitely
– you know, the probability of that, of a new primary cancer, certainly is impacting my
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decision in terms of moving forward with a mastectomy – a double mastectomy or not, so
it is very relevant’.
Many participants talked about how they delivered the news of their GPT results
to family members and their family members’ reactions to the news. An affected
individual who tested negative stated, ‘…it went well, and I think they also were worried
about the results. I think the whole family was concerned about this, and knowing the
genetic results was very important for all of us. And we knew that there was a bit of risk
on both sides of the family, so for us in particular, it was very important to know the
results’. An unaffected individual who tested positive for a BRCA2 mutation stated, ‘Well
they were both upset which then made me more upset. But my husband's very like,
typical. Typical man I'd say. Okay, well this is the problem, we're going to fix it this way,
what do you have to do kind of thing’.
A few participants highlighted the importance of having a genetic counsellor
apart of their GPT experience. One individual stated, ‘I think having the genetics
counsellor in the clinic itself, is fantastic. I don’t know if that’s standard process across
most hospitals or not, or if your study is even going to have any kind of influence on that
sort of thing, but absolutely, I mean, the fact that the genetic counsellor is in my breast
clinic, is available on a daily basis, is able to be flexible enough to come and talk to me,
you know, while I'm getting chemotherapy, explain the results, that sort of thing, I mean,
that makes all the difference. Because if it wasn’t that easy, I probably would have, you
know, maybe delayed it more, or not taken it as seriously…’ Another individual
explained, ‘… I do want to mention that I had a great time and a positive experience
talking with my counsellor. I think she did a great job of explaining to me more or less
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everything, asking the right questions and trying to understand my situation, my family
history, and trying to understand more about myself and how I developed this cancer. She
was very empathic – I think empathy was an important thing to me, the fact that you are
not just seen as a number, but a patient with an issue, and this is something extra that is
helping you. That, I think, was great – we had a good time with her’.
Some patients indicated that they had done their own research either before or
after the GPT consultation. One unaffected participant stated, ‘I had done some research
on this before and even though my mom hadn't had breast cancer the fact that I got it so
young I think that’s one of the markers for a genetic mutation... ‘
Based on their GPT results, some affected participants who tested negative now
believe that their cancer may have been due to alternative causes. One woman stated, ‘…I
have my own faith, and so to me, this was really kind of an indication that, you know,
this was an act of God and this has to do with the path I am to walk in my life, and to
some extent, that is comforting to me, to know that this is for a reason, and it’s not just
science gone amuck…And for me, I justify it as saying, okay, this is something
purposeful and there must be something I'm to learn from it, so … whereas other people
might take comfort knowing, okay, this is just genes, genetics and there’s nothing I could
do and ya-da-ya-da…’ Another participant explained, ‘Yeah, the family history is
important, it's a part of the whole story. In my case, the use of patches and birth control
pills for over twenty years… So yeah, it’s been a long time using steroids, you know, so
birth control, weight control. That, I think is a huge risk…the fact that I smoke for over
fifteen years or so, that also had an impact…The lifestyle, the food – I take a lot of red
meat, sausages, packaged ---. So a few things. I'm not doing as much exercise as I should
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do, so there are so many factors that I think that have been involved. But for sure, one of
those was – yeah, the steroids and the hormones’. In another case, a woman who tested
positive for a CHEK2 mutation originally thought her family history of cancer had
alternate causes but her GPT results changed that, ‘…through the chemicals my mom
used when she did roses for 20 years, before they stopped the poisons and
stuff. [Interviewer:

So you felt maybe the cancer might have been a result of

that.] Yeah…’
A couple of participants expressed anxiety in regards to waiting to receive their
GPT results. One woman indicated, ‘… every day was just like you’re trying to - I don't
think I've done so much yoga in my life but anyways, yeah it was definitely stressful
because as I said I thought because of my age and, you know, maternal breast cancer I
thought that the dice could, you know, not be in my favour here; and then I would be
upset that I had waited so long and had, you know, done that earlier for my daughter’.
Some participants who did not receive VUS results were asked their opinions on
how they would have felt had they received an uncertain result from their GPT. One
participant indicated, ‘I didn’t receive any inconclusive results but the thing is just I do
think there's value in it…it’s better to be proactive about it than not being proactive about
it…So I think that if something had come back inconclusive it would have just indicated
that I'm not safe. It could be … maybe a recommendation to test again in a few years, but
it actually - I think that from the way I think about things I think that, you know, it’s a
cautious approach to things …and then you could start looking at well is there anything I
can do, you know. It could reinforce how I handle my diet, exercise or whatever it is. But
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I think there is value in knowing what an inconclusive results means to a person because
prior to that I thought that inconclusive would mean…’
Two participants who did not receive VUS results still felt as though there was
some uncertainty. One participant who tested positive for a CHEK2 mutation stated, ‘…
it wasn't definitive. It's not saying I'm definitely going to get colon cancer in six months.
It's just there is a predisposition to colon cancer in my genetic background. There you
go. So it's still an if, and, or maybe. Not a definitive’. Another participant who was
affected by breast cancer but tested negative felt there was still uncertainty as to what
caused her cancer, ‘…Like I said there's always there million dollar question why did this
happen to a healthy 34 year old female right’.
Some participants used the phrase ‘the more the better’ or similar. There was also
an underlying theme of knowledge is power; that they participants felt empowered by the
information that they received as a result of this test. For example, one participant who
was affected by breast cancer but tested negative stated, ‘…being diagnosed with breast
cancer I find that I think if it come back positive it would have - I would have been
prepared for what's to come … it’s information right and information is power so I think
that having an answer even if it's not a favourable answer, you know, forces you to move
forward in one direction…’ Most participants who were asked explicitly whether they
prefer to have more information rather than less in life situations replied that this was true
for them.
Discussion
Over the past 20 years, genetic testing for breast cancer susceptibility has centred
around BRCA1/2 analysis. The discovery of additional genes involved in breast cancer
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susceptibility coupled with cheaper and faster analyses has lead to the production of gene
panel tests. This has led to increased rate of not only mutation detection, but also an
increase in VUS results. Currently, most risk assessment centres in the province of
Ontario are using or contemplating using GPTs as the routine genetic analysis in
individuals who meeting criteria for what was once only BRCA1/2 analysis. Most of this
change to GPT has been carried out within the same established protocols of genetic
counselling in high risk clinics as it has been with BRCA1/2. For example, patients who
test negative or receive a VUS result from GPT are still assessed for future breast cancer
risk using risk-modeling software. It is within this context that we asked participants of
their experiences with the provision of GPT.
Presently, more and more individuals are seeing GPT and cancer risk assessment
as the ‘next step’ in either their cancer care process or in their quest to find out why they
have a personal or family history of cancer. Many individuals are keen on being prepared
for potential future health risks and want information on how to prepare for and/or
mitigate these risks.
Our research suggests that issues surrounding GPT closely resemble issues
encountered during traditional single-gene genetic testing. One of the main issues in GPT
is pre and post-test counselling for VUS and negative test results. Patients should be
advised that a negative GPT result does not return them back to population risk for future
cancers, nor does it preclude them from having a mutation in a gene that was not included
in the panel or has not yet been discovered. Other issues surrounding GPT include testing
positive for a mutation that confers risks for additional types of cancers (some of which
may not be screenable) and implications for family members if a mutation is found.
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Participants were generally pleased with the provision of this test and the pre and
post-test counselling that they received. However, some of the opinions collected during
this research suggest that while patients are interested in having a lot of information
regarding their GPT pre and post-test, perhaps this information should be better tailored
to the patient’s preference and/or education level. Additionally, some participants wished
that there was a shorter turnaround time for results.
Participants that received VUS results generally indicated that they had a good
understanding of these results and the subsequent clinical implications (i.e. screening and
management are to based on personal/family history of cancer). Furthermore, most
participants indicated that these results did not cause much stress or strong emotional
reactions. These individuals did not seem to be very concerned or anxious regarding their
result, however some acknowledged that uncertainty is not handled the same by everyone
and that this should be taken into consideration when carrying out GPT. Some
participants took comfort in that one day uncertain results (ie. VUS results) might be
elucidated, as more data is gathered. Given these findings, one might infer that patients
are generally capable of understanding an uncertain result and would fare similarly if
uncertain results were to arise in future genetic tests.
Overall, GPT appears to be well-tolerated within the context of a traditional
genetics assessment. Participants generally had positive feelings in regards to their
experience receiving GPT and felt that they would recommend the process to others in a
similar situation.
From the inception of breast cancer genetic testing with BRCA1/2 analysis, to the
introduction of GPT within the context of a cancer risk assessment, we are now faced
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with the advent of polygenic genetic testing via whole exome, whole genome, or SNP
platforms (Li et al., 2017). SNPs, or single nucleotide polymorphisms, can be relatively
common in the general population and individually may not mean much, but when
combined may carry an additional risk for breast cancer. Recently, many of these SNP
tests have been validated however there has yet to be a widespread implementation of this
testing within the framework of a routine cancer risk assessment.
Responses from the participants in this study suggest that they would be willing to
take the next step into receiving genetic testing via these new technologies and are not
too concerned by the uncertainty that it might provide. There was a general consensus
among participants that did not receive a clinically significant result through GPT that
they would be open to pursuing future polygenic testing that looked at more genetic
elements than GPT, despite the possibility of again receiving an uncertain result.
Motivating factors for pursuing these tests resembled motivating factors for pursuing
GPT. Participants also seemed open to finding out information regarding diseases other
than cancer, however some individuals had reservations about learning about diseases for
which there is no cure or screening available.
In the future, there is the potential that all females may be offered this polygenic
test to determine proper levels of screening for individuals in the population regardless of
their familial cancer risk. In other words a more personally stratified assessment of breast
cancer risk regardless of any existing family cancer history. Participants found value in
this proposition but also had mixed responses as to whether this future polygenic testing
should be provided through their hospital, a specialty breast clinic, genetic services or
their family doctor. Many acknowledged the possible burden to these communities and
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agreed that widespread uptake of polygenic testing could take place as part of a
Provincial program that is used for population screening such as the Ontario Breast
Screening Program. If the provision of this test was to fall under the typical scenarios that
single gene and GPT currently are, issues such as education of providers and the general
public, cultural considerations, and the availability of a genetic counsellor or specialist to
personally answer questions or concerns would need to be addressed.
Study Limitations
Study participants were recruited based on their history of receiving genetic
testing at the Marvelle Koffler Breast Centre at Mount Sinai Hospital. As a result, the
opinions are reflective of the genetic counselling process at this specific hospital. While
one might hope that these opinions would be representative of patients’ experiences at
genetic testing clinics across the province of Ontario, this may not truly be the case.
Furthermore, study participants were only those who proactively returned the study
consent form to indicate their interest in study participation, or individuals who agreed to
participate after being contacted by phone. It is possible that certain opinions were
missed based on who was recruited for the study, such as participants who received
secondary findings as a result of the test or participants who had negative opinions
regarding GPT and thus were uninterested in participating in the study. Also, although we
interviewed to beyond thematic saturation, we have only interviewed a small number of
clinic participants. It is also possible that people self-selected for those who had a good
experience in the testing process.
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Practice Implications
Data obtained during the course of this research study may have implications on
future genetic testing and genetic counselling practices in Canada. Understanding the
underlying motivations and experiences of individuals who underwent GPT is critical to
providing support during the cancer genetic counselling session.
Additionally, this research will inform future polygenic testing. Given the positive
reception that GPT received during the course of this study, genetics clinics may be more
open to offering more complex, polygenic testing to patients in the near future.
Conclusions & Future Directions
The data suggests that GPT is well-tolerated within the context of a traditional
genetics assessment and that individuals would be open to pursuing future polygenic
testing within this framework to help answer the question as to why they developed
cancer or have a family history of cancer. Further quantitative research would provide
robust data on whether a larger population of individuals would be open to this more
expansive genetic testing and how individuals would prefer that it be provided.
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Appendix - 1:
Interviewee demographic characteristics
Characteristic
N = 14
Mean age in years (range)
47.6 (32 – 68)
Race/Ethnicity
Non-Hispanic White
Ashkenazi Jewish
Hispanic
Aboriginal
Mixed Ethinicity –
Indian/Pakistani/Irish/Scottish/Welsh
Mixed Ethnicity –
Aboriginal/Polish/Macedonian
Unknown

5
2
3
1
1
1
1

Marital Status
Married
Never married
Divorced/Separated/Widowed

8
5
1

Gene panel test result
Positive
VUS
Negative

3 [ATM, CHEK2 & BRCA2]
4 [ATM, PALB2, MLH1 & MLH1]
7

Cancer status
Affected
Unaffected

9
5
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Appendix – 2: Interview Questions
Developed by Gord Glendon, MSc.
Introduction
o Hello, may I please speak to X.
o This is X calling from the, Understanding Gene Panel Testing study for our
scheduled interview. Thank you for taking my call.
o As a reminder, we will be audio taping this interview and then transcribing it into a
word document. This is so we can later explore the details of what we have discussed
today. Is that alright with you? Your transcript will be identified only by a number
and will not contain any directly identifying information such as your name, address
or date of birth.
o If there is any topic or question you don’t want to talk about for any reason, just say
‘skip’ and we will move onto another question.
o Please feel free to discuss anything you would like to with respect to your genetic
counselling and testing experiences. This interview is the forum for you to speak your
mind and there are no right or wrong answers.
o Please keep in mind that we cannot give you any medical advice or answer any
questions about your results.
o A typical interview of this type could last up to 30 to 45 minutes.
o Are you ready to go ahead with the interview now?
Understanding the participants GPT experience: Defining the timeline and type of
testing
We understand that you have been seen in the Familial Breast Cancer Clinic at the
Marvelle Koffler Centre for a risk assessment within the last year. We also understand
that you had a genetic test or tests there. We would like to talk to you about how that
process took place.
Ø Can you walk us through your risk assessment process? Did you receive
genetic counselling and then testing? Did you have 2 separate tests (one
for BRCA1/2 and one called a gene panel test)?
Ø Do you know what the test you had is called (prompt for GPT)?
Ø Can you explain to me what the GPT is? Is it a blood test? What does it
look for? Is it different from the first blood test you had (BRCA1/2)? Does
it look at more than one gene at a time or only one?
Ø Did you receive the results from the genetic testing you had? If you did
would you mind sharing them with us to help us better understand the
impact the testing may have had on you?
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Ø How were the results communicated to you? Were results delivered by the
genetic counsellor or the physician or both? Was it over the phone or in
person? Did you bring someone with you or were you alone for the results
session? Did you have a follow up session with the genetics team after the
results session?
Ø How long was the process from the time of giving blood to getting the
results?
Impact of GPT for participant
We know that having genetic testing can sometimes lead to results that have a direct
effect on our health, especially when the results are positive. Even the experience of
having a negative genetic test, without getting a clinically significant result can have an
effect for some. Now, we would like to hear what impact, if any, did undergoing the GPT
have for you and possibly your family? We are interested in both how it may have
impacted your thinking and feelings as well as any impact it may have had on your health
behaviours such as screening, surgeries. Also did your results have any effect on other
family members if any (siblings, children, parents)
Ø What were you told your result means in terms of your risk for breast
cancer? What were you told the results mean with respect to the cause of
your cancer? What were you told the results means with respect to your
family’s history of cancer?
Ø Do you feel that the GPT helped to explain your personal or family history
of breast cancer? Do you feel the GPT added any information beyond
what you may have learned from your BRCA1/2 test? Do you feel that
this test added anything to your understanding of your cancer / your
family’s cancer / your breast cancer risk?
Ø Do you feel there was uncertainty in the results you received from your
test? In other words, did you receive a result that may or may not explain
your / your family’s cancer history? If so, how do you feel about that
uncertainty? Does receiving this uncertainty make you feel worse, better
or no different than before the test / after the BRCA1/2 test?
Ø In general, what are your feelings about your GPT results? Do the results
give you peace of mind / cause you to worry more about breast cancer risk
/ not change how you feel about breast cancer?
Ø Have you told anyone about having the GPT? Results? Why or why not?
Ø Did you receive a specific course of action or screening recommendations
after getting your GPT results? Did this course of action / screening
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recommendation change from what you had been recommended
previously?
Ø Do you think that you will change any of your health behaviours or cancer
screening based on the information you received in this test? Is there any
health behaviour you have wanted to change that the test result will help
motivate you to carry out? Do you feel that possibly changing aspects of
your lifestyle like diet, exercise or screening could affect your chance for
developing cancer?
Opinions and Preferences on the Provision of GPT
Now that you have gone through the process of GPT, we would like to hear about your
opinions and preferences for how the test should be delivered. This test is new in Ontario
and any feedback you have can be extremely valuable.
Ø Now that you have received your results, do you think, in retrospect, that
you had a good understanding of the possible results you could get from
the test (no increase in cancer risk to moderate increase to high increase)?
Do you feel that you had a good understanding of the complexity of the
test before you received your results? Do you feel you had a good
understanding of the wide range of clinical recommendations you could
get from the results of this test (from no change in screening to slightly
modified screening to frequent screening with a discussion of prophylactic
measures)?
Ø What would you change, if anything, about your preparation for the test?
Would you prefer more, less or the same amount of pre-test information?
Are there specific things that, in retrospect, you would have liked to know
more about? Did you feel that there was too much information presented
to you before the test, not enough or just the right amount?
Ø What would you change, if anything, about the process of receiving results
from this kind of test? Would you have liked more or less detailed
information about the results? What was your opinion on the patient letter
that was sent to you after the test? Do you feel like it helped reinforce your
results, or were you left with a greater sense of confusion?
Ø Do you feel there’s any benefit to receive test results that have no clear
implication for cancer risk or clinical management? Do you have an
opinion about the usefulness of receiving results with uncertain
significance?
Ø If you received results of unknown significance, you were likely told that
these results are typically re-classified over time and you were asked to
keep in touch with your genetics clinic every few years to see if your
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results have been re-classified. Would you prefer to be responsible for
contacting your clinic regarding any changes in classification, or you
would you prefer to have the clinic automatically contact patients instead?
Ø Would you recommend this test to others? Would you recommend this test
to others in your family?
Ø In general, what is your opinion of GPT? Are there aspects of the test that
you would not advocate for?
Ø Is there anything else you would like to discuss with respect to your
opinions or preferences for the delivery of this test? Is GPT something that
genetics clinics should continue to offer?
Future Polygenic Test
Understanding the genetic causes of familial breast cancer is constantly evolving. You
have gone through the first 2 generations of genetic testing. The first test looked at
BRCA1/2 genes. The second is GPT which examines another 20 or so genes associated
with familial breast cancer. Just over the horizon is another group of tests that will look at
a much larger part of the human genome to try and understand how cancer runs in
families. The techniques will vary but the underlying idea is that we will be able to look
at thousands of genes at the same time and something called SNPs. Individually, these
elements may not mean much, but together they will give us a much more complete
picture of breast cancer risk. You may have heard of whole genome sequencing which is
an example of this. The promise of these tests is that they may be able identify someone’s
cancer risk from very low to very high allowing better screening and treatment, but also
your risk to develop other diseases. We would like to get your reaction to such a possible
test.
Ø If this test was available as I described it, would you be motivated to have
it? Why or why not? Was there anything in your experience with GPT that
would make it more or less likely to be interested in this type of more
comprehensive test?
Ø If this test had a possibility of giving a result of uncertain clinical
usefulness, would that make you more or less likely to pursue it? Why or
why not?
Ø It is possible that such a test could also reveal risks for diseases other than
cancer. If this was the case, would you like to know about those other risks
as well? Why or why not? Do you think that if you have a test for cancer
risk, the results should be strictly related to cancer or include risks for
other diseases? Would you want to know about results that show that you
are at risk for something but there was nothing you could do to reduce that
risk?
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Ø If a company provided this test directly to the public, outside of the
medical system, and was reasonably priced, would you consider having it?
Why or why not? Do you feel that these types of tests should be provided
only by a doctor in an established medical setting to patients who meet
criteria for testing, or be available to anyone who wants to have it and is
willing to pay out of pocket for the information?
Conclusion
Thank you very much for talking with us today. Your thoughts and suggestions are very
valuable in helping health professionals to provide the best possible service going
forward.
Ø Do you have anything else you would like to discuss with respect to GPT?
Feel free to comment on anything we discussed earlier or anything we
didn’t cover that you may feel is important.
Ø Thanks again for your contribution.

45

